Compare BioNTech SE - ADR (BNTX) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Microchip Technology Inc. — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while Microchip Technology Inc. trades at $80.65 (market cap $43.99B). The key difference: Microchip Technology Inc. is the larger of the two by market cap, and Microchip Technology Inc. pays a 2.25% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | MCHP | |
|---|---|---|
Market Cap | $23.31B | $43.99B |
Sector | Health | Technology |
52-Week High | $119.34 | $102.97 |
52-Week Low | $83.89 | $49.02 |
Enterprise Value | $6.60B | $49.12B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Microchip Technology (MCHP) trades at $80.45, down 1.15% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings beats, including Q1 2026 EPS of $0.57 versus $0.505 expected (Zacks Investment Research, 2026-08-07), highlight robust demand recovery and data center growth. The company maintains solid profitability with a 60.19% gross margin but faces high valuation multiples like a P/E of 119.15.
The outlook is positive driven by AI and data center expansion, with a consensus price target of $104.00 (MarketBeat, 2026-08-07). Risks include elevated debt levels and sensitivity to semiconductor cycles. Upside potential exists if execution continues to exceed expectations amid broadening demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
